NOVEL STRATEGIES FOR THE IMMUNOTHERAPY OF COLON CANCER
NOVEL STRATEGIES FOR THE IMMUNOTHERAPY OF COLON CANCER
批准号:
6633541
负责人:
RALPH A. REISFELD
金额:
$41.67万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-05-08 至 2005-04-30
关键词:
Listeria Salmonella typhimurium antigen presentation carcinoembryonal antigen chimeric proteins colon neoplasms cytotoxic T lymphocyte disease /disorder model genetically modified animals laboratory mouse neoplasm /cancer immunology neoplasm /cancer immunotherapy neoplasm /cancer vaccine nonhuman therapy evaluation passive immunization proteasome ubiquitin vaccine development vector vaccine
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Adapted from applicant's abstract) The overall objective is to
construct and optimize novel human CEA-based DNA vaccines for the effective
immunotherapy of colon carcinoma. The investigators will test the hypothesis
that peripheral T cell tolerance to these tumor self-antigens can be overcome
by DNA vaccines boosted by effective adjuvants designed to generate cytolytic T
lymphocyte (CTLs) specific for CEA epitopes expressed as MHC class I complexes
on colon carcinoma cells. Emphasis will be on optimizing antigen processing and
presentation in mouse models either transgenic for CEA or double transgenic for
CEA and HLA-A2.1Kb. Their aim is to use such models for optimization of vaccine
by antibody-cytokine fusion proteins and to investigate basic concepts such as
mechanisms of T cell co-stimulation, generation of tumor-specific CTLs and T
memory cells and establish principles for adoptive immunotherapy. The specific
aims designed to achieve these objectives are: 1) construction of optimal human
CEA-specific DNA vaccines containing first the entire CEA gene and then
minigenes encoding specific CEA peptides with HLA-A*0201 anchor residues.
Delivery of the vaccines by injction of naked KNA or orally by galvage using
attenuated strains of either Salmonella typhimurium or Listeria monocytogenes;
2) optimization of antigen processing in the 20S proteasome and presentation by
using ubiquitinated versions of the entire CEA gene, minigenes encoding several
CEA nonapeptides organized as as a string of beads or direct targeting of
single CEA or repeat epitopes to the endoplasmic reticulum; 3) achievement of
optimal adjuvanticity using either unmethylated CpG dinucleotide motifs or CD40
Ligand/Trimer co-expression; and 4) determination whether antibody-IL2 fusion
proteins can effectively boost DNA vaccines to achieve optimal, long-lived
tumor-protective immunity, as well as eradicate established metastases, and
identification of immunological mechanisms involved in generating
tumor-specific CTLs and T memory cells. The achievement of this proposal's
objectives should lead to the design of effective DNA vaccines based on
rational immunological principles that may ultimately lead to the improved
treatment of colon cancer.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1182/blood-2005-10-4231
发表时间:
2006-04
期刊:
Blood
影响因子:
20.3
作者:
[He Zhou;Yunping Luo;C. Kaplan;J. A. Krüger;Sung‐Hyung Lee;R. Xiang;R. Reisfeld]
通讯作者:
He Zhou;Yunping Luo;C. Kaplan;J. A. Krüger;Sung‐Hyung Lee;R. Xiang;R. Reisfeld
DOI:
10.1158/0008-5472.553.65.2
发表时间:
2005-01
期刊:
Cancer research
影响因子:
11.2
作者:
[R. Xiang;N. Mizutani;Yunping Luo;C. Chiodoni;He Zhou;M. Mizutani;Y. Ba;J. Becker;R. Reisfeld]
通讯作者:
R. Xiang;N. Mizutani;Yunping Luo;C. Chiodoni;He Zhou;M. Mizutani;Y. Ba;J. Becker;R. Reisfeld
DOI:
10.1073/pnas.0502208102
发表时间:
2005-08
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[He Zhou;Yunping Luo;Jeng-Fan Lo;C. Kaplan;M. Mizutani;N. Mizutani;Jiing-Dwan Lee;F. Primus;J. Becker;R. Xiang;R. Reisfeld]
通讯作者:
He Zhou;Yunping Luo;Jeng-Fan Lo;C. Kaplan;M. Mizutani;N. Mizutani;Jiing-Dwan Lee;F. Primus;J. Becker;R. Xiang;R. Reisfeld
DOI:
--
发表时间:
2001-12
期刊:
Cancer research
影响因子:
11.2
作者:
[J. Ruehlmann;Rong Xiang;A. Niethammer;Yi Ba;U. Pertl;C. Dolman;S. D. Gillies;Ralph A. Reisfeld]
通讯作者:
J. Ruehlmann;Rong Xiang;A. Niethammer;Yi Ba;U. Pertl;C. Dolman;S. D. Gillies;Ralph A. Reisfeld
DOI:
10.1615/critrevoncog.v18.i1-2.70
发表时间:
2013
期刊:
Critical reviews in oncogenesis
影响因子:
--
作者:
[R. Reisfeld]
通讯作者:
R. Reisfeld
共 6 条
Targeting of STAT3 Signaling Enhances Efficacy of Breast Cancer Immunotherapy
-
批准号:8034729
-
项目类别:
-
资助金额:$38.22万
-
财政年份:2009
-
负责人:RALPH A. REISFELD
-
依托单位:
Targeting of STAT3 Signaling Enhances Efficacy of Breast Cancer Immunotherapy
-
批准号:7663038
-
项目类别:
-
资助金额:$39.4万
-
财政年份:2009
-
负责人:RALPH A. REISFELD
-
依托单位:
Fra-1: A new target for a genomic breast cancer vaccine
-
批准号:7360310
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2006
-
负责人:RALPH A. REISFELD
-
依托单位:
Fra-1: A new target for a genomic breast cancer vaccine
-
批准号:7100348
-
项目类别:
-
资助金额:$33.0万
-
财政年份:2006
-
负责人:RALPH A. REISFELD
-
依托单位:
Fra-1: A new target for a genomic breast cancer vaccine
-
批准号:7574393
-
项目类别:
-
资助金额:$32.66万
-
财政年份:2006
-
负责人:RALPH A. REISFELD
-
依托单位:
Fra-1: A new target for a genomic breast cancer vaccine
-
批准号:7212238
-
项目类别:
-
资助金额:$32.04万
-
财政年份:2006
-
负责人:RALPH A. REISFELD
-
依托单位:
NOVEL STRATEGIES FOR THE IMMUNOTHERAPY OF COLON CANCER
-
批准号:6514229
-
项目类别:
-
资助金额:$41.67万
-
财政年份:2000
-
负责人:RALPH A. REISFELD
-
依托单位:
NOVEL STRATEGIES FOR THE IMMUNOTHERAPY OF COLON CANCER
-
批准号:6377619
-
项目类别:
-
资助金额:$39.89万
-
财政年份:2000
-
负责人:RALPH A. REISFELD
-
依托单位:
NOVEL STRATEGIES FOR THE IMMUNOTHERAPY OF COLON CANCER
-
批准号:6196918
-
项目类别:
-
资助金额:$39.89万
-
财政年份:2000
-
负责人:RALPH A. REISFELD
-
依托单位:
IMMUNOTHERAPEUTIC MODULATION OF ANGIOGENESIS IN CANCER
-
批准号:2907651
-
项目类别:
-
资助金额:$13.36万
-
财政年份:1999
-
负责人:RALPH A. REISFELD
-
依托单位:
IMMUNOTHERAPEUTIC MODULATION OF ANGIOGENESIS IN CANCER
-
批准号:6173843
-
项目类别:
-
资助金额:$11.45万
-
财政年份:1999
-
负责人:RALPH A. REISFELD
-
依托单位:
CYTOKINE AND ANTI-RECEPTOR ANTIBODY FUSION PROTEINS
-
批准号:6102194
-
项目类别:
-
资助金额:$0.0万
-
财政年份:1997
-
负责人:RALPH A. REISFELD
-
依托单位:
MOLECULAR APPROACHES TO CANCER IMMUNOTHERAPY
-
批准号:3434322
-
项目类别:
-
资助金额:$0.3万
-
财政年份:1993
-
负责人:RALPH A. REISFELD
-
依托单位:
NEW TUMOR MODELS FOR THE DEVELOPMENT OF IMMUNOTHERAPY
-
批准号:3549514
-
项目类别:
-
资助金额:$28.01万
-
财政年份:1990
-
负责人:RALPH A. REISFELD
-
依托单位:
NEW TUMOR MODELS FOR THE DEVELOPMENT OF IMMUNOTHERAPY
-
批准号:3549515
-
项目类别:
-
资助金额:$26.83万
-
财政年份:1990
-
负责人:RALPH A. REISFELD
-
依托单位:
NEW TUMOR MODELS FOR THE DEVELOPMENT OF IMMUNOTHERAPY
-
批准号:3549516
-
项目类别:
-
资助金额:$29.78万
-
财政年份:1990
-
负责人:RALPH A. REISFELD
-
依托单位:
MOLECULAR PROFILE OF MELANOMA AND NEUROBLASTOMA ANTIGENS
-
批准号:2090776
-
项目类别:
-
资助金额:$77.86万
-
财政年份:1986
-
负责人:RALPH A. REISFELD
-
依托单位:
MOLECULAR PROFILE OF MELANOMA AND NEUROBLASTOMA ANTIGENS
-
批准号:2390677
-
项目类别:
-
资助金额:$89.02万
-
财政年份:1986
-
负责人:RALPH A. REISFELD
-
依托单位:
MOLECULAR PROFILE OF MELANOMA AND NEUROBLASTOMA ANTIGENS
-
批准号:3479330
-
项目类别:
-
资助金额:$76.36万
-
财政年份:1986
-
负责人:RALPH A. REISFELD
-
依托单位:
MOLECULAR PROFILE OF MELANOMA AND NEUROBLASTOMA ANTIGENS
-
批准号:3479334
-
项目类别:
-
资助金额:$68.78万
-
财政年份:1986
-
负责人:RALPH A. REISFELD
-
依托单位:
海外基金